NASDAQ:HSKA - Heska Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heska Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $106.83 +1.17 (+1.11 %) (As of 01/23/2020 06:11 AM ET) Add Compare Today's Range$106.47Now: $106.83▼$109.7050-Day Range$93.46MA: $97.41▼$107.9352-Week Range$62.47Now: $106.83▼$110.90Volume127,904 shsAverage Volume78,254 shsMarket Capitalization$836.48 millionP/E Ratio227.30Dividend YieldN/ABeta1.1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA Previous Symbol CUSIPN/A CIK1038133 Webhttp://www.heska.com/ Phone970-493-7272Debt Debt-to-Equity Ratio0.31 Current Ratio8.52 Quick Ratio6.80Price-To-Earnings Trailing P/E Ratio227.30 Forward P/E Ratio2,136.60 P/E GrowthN/A Sales & Book Value Annual Sales$127.45 million Price / Sales6.56 Cash Flow$2.10 per share Price / Cash Flow50.89 Book Value$16.13 per share Price / Book6.62Profitability EPS (Most Recent Fiscal Year)$1.42 Net Income$5.85 million Net Margins3.15% Return on Equity3.17% Return on Assets2.34%Miscellaneous Employees347 Outstanding Shares7,830,000Market Cap$836.48 million Next Earnings Date2/25/2020 (Estimated) OptionableNot Optionable Receive HSKA News and Ratings via Email Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HSKA Rates by TradingView Heska (NASDAQ:HSKA) Frequently Asked Questions What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." How were Heska's earnings last quarter? Heska Corp (NASDAQ:HSKA) posted its quarterly earnings results on Tuesday, November, 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The medical research company had revenue of $31.24 million for the quarter, compared to analysts' expectations of $30.44 million. Heska had a net margin of 3.15% and a return on equity of 3.17%. View Heska's Earnings History. When is Heska's next earnings date? Heska is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Heska. What price target have analysts set for HSKA? 8 equities research analysts have issued 1-year target prices for Heska's stock. Their forecasts range from $68.00 to $107.00. On average, they anticipate Heska's stock price to reach $88.80 in the next year. This suggests that the stock has a possible downside of 16.9%. View Analyst Price Targets for Heska. What is the consensus analysts' recommendation for Heska? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Heska. What are Wall Street analysts saying about Heska stock? Here are some recent quotes from research analysts about Heska stock: 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (11/15/2019) 2. Canaccord Genuity analysts commented, "We view this financing as overdue" as the company had been operating for some time at a cash balance hovering around $10 million. We trim our out year revenue and earnings estimates as we exercise more conservatism on Heska’s top line growth, and we expect a higher level of spending to help return the company to growth, following ~3 years of missing expectations. We are cautiously optimistic to see Heska deliver on its growth initiatives, however, our near-term expectations are tempered until we see evidence of stronger commercial execution. While we trim our estimates and price target to $75 (from $95), we are sticking with our BUY rating in hopes we see progress on new product and geographic expansion as we look out to 2020. Convertible notes." (9/12/2019) Has Heska been receiving favorable news coverage? Press coverage about HSKA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heska earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Heska. Who are some of Heska's key competitors? Some companies that are related to Heska include Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO) and GeneNews (GNWSF). What other stocks do shareholders of Heska own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Broadcom (AVGO), Biogen (BIIB), Netflix (NFLX), Western Digital (WDC), Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Exxon Mobil (XOM), AT&T (T) and Amgen (AMGN). Who are Heska's key executives? Heska's management team includes the folowing people: Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44) Who are Heska's major shareholders? Heska's stock is owned by a number of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (3.70%), Johanson Financial Advisors Inc. (0.51%), Louisiana State Employees Retirement System (0.03%) and Raymond James Trust N.A. (0.03%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska. Which major investors are selling Heska stock? HSKA stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC. View Insider Buying and Selling for Heska. Which major investors are buying Heska stock? HSKA stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Louisiana State Employees Retirement System and Raymond James Trust N.A.. View Insider Buying and Selling for Heska. How do I buy shares of Heska? Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $106.83. How big of a company is Heska? Heska has a market capitalization of $836.48 million and generates $127.45 million in revenue each year. The medical research company earns $5.85 million in net income (profit) each year or $1.42 on an earnings per share basis. Heska employs 347 workers across the globe.View Additional Information About Heska. What is Heska's official website? The official website for Heska is http://www.heska.com/. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected] MarketBeat Community Rating for Heska (NASDAQ HSKA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 338 (Vote Underperform)Total Votes: 646MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2020 by MarketBeat.com StaffFeatured Article: Balance Sheet
